May 17, 2020

Aging populations are a captive market for the medical device industry

Aging population
Capitve market
Medical device industry
Europe
Fran Roberts
3 min
With 23% of the population currently aged 60 or older, Europe is home to a relatively aged population.

This is a result of the higher life expectancy...

With 23% of the population currently aged 60 or older, Europe is home to a relatively aged population.

This is a result of the higher life expectancy and decreased birth and mortality rates.

By 2030, more than 25% of the population in Europe will be 60 or older. The growing senior population is an important growth driver for health care.

Of course, it is not just Europe where the population is aging.

According to a 2015 review by the World Health Organisation (WHO) approximately one in nine people is aged 60 years or over.

In Japan, the challenge of population ageing is particularly pronounced, as people over the age of 65 years account for 23% of the population while people under the age of 15 years only account for 13% of the population.

According to Johnson & Johnson, “people over the age of 65 years use approximately seven times more health care-related products and services than younger people”.

This is good news for the medical devices industry.

The medical devices industry is a major employer in Europe, employing 575,000 people in the EU.

Total sales amount to €100bn, according to the European Commission.

SEE ALSO:

The sector represents some 25,000 companies, of which 95% are Small and Medium-sized Enterprises (SMEs).

“From a macroeconomic standpoint, certainly, we have an aging population,” said Peter Huie, VP Supply Chain & Facilities, Millstone Medical.

“We have 18,000 Americans alone that turn 65 every day for the next 18 years.”

“So, there's certainly a captive audience for our business to grow.”

Indeed, according to the US Census Bureau, the majority of the American Baby Boomer population turns 65 between 2010 and 2020. 

That number, at its height, will account for 28% of the total population.

As medical device innovation progresses to meet the challenges of an aging population, many regulatory bodies are struggling to keep apace.

According to an Emergo survey of Quality Assurance/Regulatory Affairs professionals published in January 2015, regulatory compliance is becoming more difficult for medical device companies around the globe. 

In fact, over 35% of respondents reported that obtaining regulatory approval in the US is more difficult today than it was one year ago.

“The ever-changing landscape of FDA requirements, ISO requirements – here's always a challenge in making sure that you're up to date with meeting those requirements,” said Tom Williams, General Manager, Millstone Medical.

“Balancing those and the 50 different customers we have and the 50 different requirements that come with those customers, and being able to balance it all to ensure that we're providing a robust service is a challenge.”

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article